Fintel reports that on April 19, 2023, Needham reiterated coverage of Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy recommendation.
Analyst Price Forecast Suggests 68.10% Upside
As of April 6, 2023, the average one-year price target for Phathom Pharmaceuticals is $18.02. The forecasts range from a low of $9.09 to a high of $25.20. The average price target represents an increase of 68.10% from its latest reported closing price of $10.72.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Phathom Pharmaceuticals is $37MM. The projected annual non-GAAP EPS is -$5.64.
What are Other Shareholders Doing?
Rothschild Asset Management holds 246K shares representing 0.56% ownership of the company. In it's prior filing, the firm reported owning 207K shares, representing an increase of 15.56%. The firm increased its portfolio allocation in PHAT by 6.64% over the last quarter.
AIM INTERNATIONAL MUTUAL FUNDS (INVESCO INTERNATIONAL MUTUAL FUNDS) - Invesco Oppenheimer Global Fund Class C holds 1,123K shares representing 2.58% ownership of the company. No change in the last quarter.
SSMHX - State Street Small holds 8K shares representing 0.02% ownership of the company. In it's prior filing, the firm reported owning 7K shares, representing an increase of 9.33%. The firm increased its portfolio allocation in PHAT by 2.92% over the last quarter.
URTY - ProShares UltraPro Russell2000 holds 2K shares representing 0.00% ownership of the company. In it's prior filing, the firm reported owning 2K shares, representing an increase of 17.38%. The firm increased its portfolio allocation in PHAT by 31.80% over the last quarter.
Deutsche Bank Ag\ holds 11K shares representing 0.02% ownership of the company. No change in the last quarter.
What is the Fund Sentiment?
There are 219 funds or institutions reporting positions in Phathom Pharmaceuticals. This is a decrease of 10 owner(s) or 4.37% in the last quarter. Average portfolio weight of all funds dedicated to PHAT is 0.08%, a decrease of 48.35%. Total shares owned by institutions decreased in the last three months by 7.45% to 31,352K shares. 
The put/call ratio of PHAT is 0.08, indicating a bullish outlook.
Phathom Pharmaceuticals Background Information
(This description is provided by the company.)
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders.
See all Phathom Pharmaceuticals regulatory filings.This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
